Open AccessAcquired pure red cell aplasia and recombinant erythropoietin
Author(s) -
Somanath Padhi,
Sandip K Panda
Publication year - 2021
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_229_20
Subject(s) - pure red cell aplasia , erythropoietin , erythropoiesis , medicine , anemia , recombinant dna , pathophysiology , kidney disease , nephrology , red cell , clinical practice , aplasia , disease , intensive care medicine , biology , physical therapy , biochemistry , gene
Recombinant erythropoietin (rEPO)-associated immunologically driven acquired pure red cell aplasia (PRCA) is an underreported, potentially worsening clinical syndrome in the setting of treatment of anemia of chronic kidney disease. Most cases reported in world literature are related to different formulations of erythropoiesis-stimulating agents with an implication in diagnosis and management. This brief review highlights the clinical guidelines of rEPO usage in nephrology practice, the pathophysiologic mechanism of PRCA, clinical features, diagnosis, and suggested management protocols.